Resilience support for adolescents and young adults with sickle cell disease
Official title: Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
Run by Boston Children's Hospital · NCT06555939 · Data updated 2026-11-12
This project will test a resilience-building program (PRISM) delivered through a collaborative care model for adolescents and young adults with sickle cell disease to see if it is feasible and acceptable.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years to 25 Years |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Boston Children's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | October 23, 2025 |
| Main results expected | September 2029 |
| Study ends | September 2030 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT06555939 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are English- or Spanish-speaking patients aged 8–25 with sickle cell disease who receive care at the DFCI/BCH Blood Disorders Center and score above 9 on the PHQ-9 or a GAD measure, and who are cognitively able to participate.
✕Probably not a fit
Patients outside the 8–25 age range, those not receiving care at the DFCI/BCH clinic, non–English/Spanish speakers, or those with cognitive limitations that preclude participation are unlikely to benefit from this pilot.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot enrolls 25 adolescents and young adults (ages 8–25) with sickle cell disease who receive care at the Dana-Farber/Boston Children's Hospital blood disorders clinic to receive the PRISM resilience intervention within a Collaborative Care Model. The primary aim is feasibility, defined in part by enrollment greater than 50%, with secondary measures of acceptability and patient satisfaction. Exploratory outcomes include changes in depression, anxiety, and pain interference measured by standard patient-reported instruments. Sessions and surveys are offered in English or Spanish and require cognitive ability to participate and complete questionnaires.
Why it matters
Potential benefit: If successful, the program could improve coping, reduce depression and anxiety symptoms, and lower pain-related interference for young people with sickle cell disease.
How similar studies have gone: PRISM and comparable resilience interventions have shown feasibility and acceptability in oncology populations, but applying this collaborative-care delivery approach to sickle cell disease is largely novel and under-tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥ 8 and ≤ 25 years of age at baseline * Diagnosed with Sickle Cell Disease (HbSS, HbSC, HbS-Beta Thalassemia, and other related hemoglobinopathies) * Receiving Medical Care at the DFCI/BCH Blood Disorders Center. * Scored \> 9 on Patient Health Questionnaire 9-item (PHQ-9) or Generalized Anxiety Disorder (GAD) * Able to speak English or Spanish language (for PRISM sessions) * Able to read English or Spanish language (for completion of surveys) * Cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator * Willing and able to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: \* does not meet above criteria
Where it's running
-
Boston Children's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Abby Rosenberg, MD
- Email: abbyr_rosenberg@dfci.harvard.edu
- Phone: 617.632.5286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.